CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

IDWeek 2020

Infectious Diseases Week 2020

October 22-25, 2020
Virtual

Posters

Posters

Dolutegravir

Ait-Khaled M, et al. Impact of treatment adherence on efficacy of DTG + 3TC and DTG + TDF/FTC: pooled analysis of the GEMINI 1 and 2 clinical studies. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1024.

Cabotegravir

Arthurs E, et al. Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada: Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1018.

Chounta V, et al. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1035.

Czarnogorski M, et al. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE). Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1037.

Garris C, et al. Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Interim Results from the CUSTOMIZE study. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1034.

Smith G, et al. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 638.

Talarico C, et al. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1021.

Teichner P, et al. Long-Term Patient Adherence and Management of Treatment Interruptions with Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1029.

Fostemsavir

Nguyen D, et al. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1315.

Disease State

de los Rios P, et al. Haves vs. Have-Nots in Healthcare Communication: Examining the Paradox Where PLHIV Who Need Quality Discussions with their Providers the Most, Access it the Least. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1017.

de los Rios P, et al. Treatment-Related Physical, Emotional, and Psychosocial Challenges and their Impact on Indicators of Quality of Life. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1045.

Karris M, et al. Characteristics Associated with Pain in Older People Living with HIV. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 929.

Leonard M, et al. Clinical Decision Support System Alerts for HIV Retention in Care – A Pilot Implementation Research Study. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1004.

Mazonson P, et al. Older Gay Black Men Living with HIV Report Higher Quality of Life than Older Gay White Men, Despite Facing Additional Burdens. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 943.

Priest J, et al. Healthcare Resource Utilization and Cost of People Living with HIV (PLWH) in US Commercial and Medicare Advantage Health Plans. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1019.

Rawlings K, et al. Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH). Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1704.

Oral Presentations

Oral Presentations

 

Cabotegravir

Czarnogorski M, et al. Summary of COVID-Related Impact on the Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Dosing Across the Six Largest Phase III and IIIb/IV Ongoing Clinical Trials. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Oral Presentation.
Saturday, October 24, 2020 11:00am — 11:10am EDT Location: Channel 1

Mills A, et al. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in HIV-positive Subjects: Results from the POLAR Study. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Oral Presentation 116.